Related Experiment Video
Updated: Jun 6, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Precision Medicine for Acute Lymphoblastic Leukemia in Children: A Review
Anish Ray1, Michael Levitt2, Toluwalope Efunkoya1
1Cook Children's Medical Center, Fort Worth, TX 76104, USA.
Insights
Childhood acute lymphoblastic leukemia survival has greatly improved, but relapsed cases remain challenging. Precision medicine, using genetics and lifestyle, offers new hope for tailored therapies and better outcomes.
Area of Science:
- Pediatric Oncology
- Hematology
- Genomics
Background:
- Childhood acute lymphoblastic leukemia (ALL) survival rates have dramatically increased, exceeding 90% in some subgroups.
- Despite advances, outcomes for patients with relapsed ALL remain poor, presenting significant long-term health challenges for survivors.
Purpose of the Study:
- To highlight the advancements in treating childhood acute lymphoblastic leukemia.
- To discuss the challenges associated with relapsed disease and long-term survivorship.
- To explore the potential of precision medicine in improving outcomes for ALL patients.
Main Methods:
- Review of clinical outcomes and survival data for childhood acute lymphoblastic leukemia.
- Analysis of the impact of tumor sequencing on identifying new leukemia subtypes.
- Discussion of the principles and potential applications of precision medicine in oncology.
Main Results:
- Survival rates for childhood acute lymphoblastic leukemia have surpassed 90% for certain patient groups.
- Relapsed acute lymphoblastic leukemia continues to present a significant therapeutic challenge.
- Tumor sequencing has revealed previously unrecognized leukemia subtypes.
Conclusions:
- Precision medicine holds promise for tailoring treatments to individual patients, improving efficacy, and reducing toxicity.
- Further integration of genomic data and personalized approaches is crucial for advancing care in pediatric leukemia.
- Continued research is essential to overcome challenges in relapsed disease and enhance the quality of life for survivors.
Abstract:
The clinical outcome for children diagnosed with acute lymphoblastic leukemia is a testimony to the success of modern medicine. Over the past few decades, survival has climbed from ∼10% to >90% for certain subgroups. Yet, the outcome for those with relapsed disease is often poor, and survivors struggle with a multitude of healthcare issues, some of which are lifelong. In recent years, the advent of the widespread sequencing of tumors has made available patients with previously unrecognized subtypes of leukemia, who have the potential to benefit from the addition of targeted therapies. Indeed, the promise of precision medicine, encompassing a person's environment, genetics and lifestyle, is likely to have profound impact on further tailoring therapies that are likely to improve outcomes, diminish toxicity and ultimately pave the pathway for a healthier population.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...